A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia-Reference-Cited by-同舟云学术

A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia

Published:2019-01-21 Issue:3 Volume:19 Page:287-298
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Petrou Panagiotis¹

Affiliation:

1. Pharmacoepidemiology-Pharmacovigilance, Pharmacy Programme, Department of Life and Health Sciences, School of Science and Engineering, University of Nicosia, Nicosia, Cyprus

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1567336

Reference32 articles.

1. Hyperphosphataemia: Treatment Options

2. The Case against Calcium-Based Phosphate Binders

3. Calcium-Based Phosphate Binders Are Appropriate in Chronic Renal Failure

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations;The European Journal of Health Economics;2021-03-06

2. Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment;Expert Review of Pharmacoeconomics & Outcomes Research;2020-09-24

3. Renal bone disease: a dietitian's perspective;Journal of Kidney Care;2020-01-02